Inventors:

Al-Obeidi et al.

Serial No.:

09/211,715

Filed:

December 14, 1998

Page 2

which is a continuation of prior application serial no. 08/428,404, filed April 25, 1995, which is a continuation-in-part of prior application serial no. 08/233,054, filed April 26, 1994, all of which are incorporated herein by reference.

A "marked" version of this paragraph that shows the actual amendments is included as Appendix A.

In The Claims

Please cancel claims 1, and 12 to 19.

Please insert the following amended claims in the specification.

2. (amended) A non-naturally occurring compound that specifically inhibits the activity of factor Xa, having the general formula $A_1-A_2-(A_3)_m-B$, wherein m is 1;

wherein A_1 is $R_1-R_2-R_3$; A_2 is $R_4-R_5-R_6$; A_3 is $R_7-R_8-R_9$;

Inventors: Al-Obeidi et al.


Serial No.:

09/211,715

Filed: Page 3 December 14, 1998

wherein

 R_1 is



X is N;

- R'1 is selected from the group consisting of isobutyl, 2-methylpentyl, cyclohexylmethyl, cyclohexenylmethyl, 2-methylbutyl, -H and 2,3-dimethylpentyl;
- R". is selected from the group consisting of 2benzofuroyl, alloc, acetyl, trifluoroacetyl, 2quinolinoyl, 3-pyridoyl, 4-isoquinolinoyl, 5-benzylimidazoyl, 2-naphthylmethyl, 5-pyridiminoyl, benzoyl, 2-pyridoyl, tosyl, 3-quinolinoyl, 2-naphthylsulfonyl, 2-methylbenzyl, 2-furoyl, 3,4-dichlorobenzoyl, 2-thienylacetyl, N(5-methyl-2-thienyl), ethoxycarbonyl, 2-fluorobenzoyl, t-butoxycarbonyl, benzyl and 1-20 amino acids;
- F- is $-CF_{0a}R_{0a}$, wherein $-R_{0a}$ and $-R_{0a}$ are independently selected from the group consisting of -H, 4amidinophenylmethyl, 4-aminophenylmethyl), 4-hydroxyphenylmethyl, 2-naphthylmethyl,

Serial No.:

Inventors: Al-Obeidi et al. 09/211,715

Filed: Page 4

December 14, 1998

4-(N-methylpyridinyl) methyl,

(3-iodo-4-aminophenyl) methyl,

(4-aminocarbonylphenyl) methyl,

(3-iodo-4-hydroxyphenyl) methyl, and

(4-cyanophenyl) methyl, (4-hydroxyphenyl) methyl;

 P_3 is -C(0)-;

 F_4 is -NH-;

 F_5 is $-CF_{5A}R_{5B}$, wherein $-R_{5A}$ and $-R_{5B}$ are independently selected from the group consisting of -H, 2-butyl, and cyclohexyl;

 F_6 is -0(0)-;

 P_7 is -NH-;

 R_{8} is -CF $_{\circ A}R_{\circ B}$, wherein -R $_{8A}$ and -R $_{8B}$ are independently selected from the group consisting of -H, 3-guanylpropyl, (dimethylamidinium)aminomethyl, (dimethylamidinium)aminoethyl, 3-(N-methylpyridinyl) methyl, and 4-(N-methylpyridinyl) methyl;

 F_{cs} is -C(0)-; and

E is Leu-Pro-NH₀, Leu-Hyp-NH₀, Pen(CH₀COOH)-Pro-NH₀, Cys(CH+COOH) -Pro-NH-, y-carboxyglutamic

Inventors: Serial No.: Al-Obeidi et al. 09/111,715 December 14, 1998

Filed: Page 5

acid-Pro-NH₂, (N-carboxymethyl)Gly-Pro-NH₂, (N-carboxyethyl)Gly-Pro-NH₂, (N-1,3-dicarboxypropyl)Gly-Pro-NH₂, (N-methyl)Leu-Pro-NH₃, Leu-NH₂, Leu-OH, -NH-(4-tramethylammoniumbenzyl), -NH-[4-(1-methylpyridinium)methyl], and -NH-(4-amidinobenzyl).

3. (amended) A non-naturally occurring compound that specifically inhibits the activity of factor Xa, having the general formula $A_1-A_2-(A_3)_m-B$, wherein m is 1;

wherein A_1 is $E_1-E_2-R_3$; A_5 is $R_4-R_5-R_6$; A_3 is $R_5-R_8-R_9$;

wherein

F is

$$R'_1 \longrightarrow X - - i$$

X is N;

E': is selected from the group consisting of H, is:butyl, 2-methylpentyl, cyclohexylmethyl, 3-quinolinyl, 2-methylbutyl, 2,3 dimethyl pentyl, and cyclohexenylmethyl;

 R''_1 is selected from the group consisting of 2-

İ

Inventors:
Serial No.:

Filed: Page 6

Al-Obeidi et al. 09/111,715

December 14, 1998

benzofuroyl, alloc, acetyl, triflucroacetyl, 2-quinolinoyl, 3-pyridoyl, 4-isoquinolinoyl, 5-benzimidazoyl, 2-naphthylmethyl, 5-pyrazinoyl, benzoyl, 2-pyridoyl, tosyl, 3-quinolinoyl, 2-naphthylsulfonyl, 2-methylbenzyl, and benzyl;

R₂ is -CR_{1A}R_{2B}, wherein -R_{2A} and -R_{2B} are independently selected from the group consisting of H, 3-amidinophenylmethyl, 4-amidinophenylmethyl, 4-amidinophenylmethyl, 2-naphthylmethyl, 4-(N-methylpyridinyl)methyl, (3-iodo-4-aminophenyl)methyl, (4-aminocarbonylphenyl)methyl, (3-iodo-4-hydroxyphenyl)methyl, (4-cyanophenyl)methyl, and 3-indolylmethyl;

 R_3 is selected from the group consisting of -C(0)-, $-CH_2$ -, $-CHR_{99}$ -C(0)- and -C(0)- NR_{35} - CH_2 -C(0)-, wherein R_{35} is the CHR_{55} group of the bridging group -C(0)- CR_{55} -;

R₄ is -NH-;

 R_{5} is $-CR_{5A}R_{5B}$, wherein $-R_{5A}$ and $-R_{5B}$ are independently selected from the group consisting of -H, 2-butyl, cyclohexyl and phenyl;

Inventors: Al-Obeidi et al.
Serial No.: 09/211,715

Filed:

December 14, 1998

Page 7

 R_{r} is -C(0)-;

F- is -NH-;

Fig. is -CR_{6A}R_{6B}, wherein -R_{6A} and -F_{6B} are independently selected from the group consisting of -H, 3-guanylpropyl, (dimethylamidinium)aminomethyl, (dimethylamidinium)aminoethyl, 3-(N-methylpyridinyl)methyl, N(carboxymethyl)(3-pyridinylmethyl), and 4-(N-methylpyridinyl)methyl;

 F_{aa} is selected from the group consisting of -C(0)-, -C(0)- and $-CHR_{aa}-C(0)$ -; and

B is -NH₂, -OH, Leu-Pro-NH₂, Leu-Hyp-NH₂,
Pen(CH₂COOH)-Pro-NH₂, Cys(CH₂COOH)-Pro-NH₂,

γ-carboxyglutamic acid-Pro-NH₂,
(N-carboxymethyl)Gly-Pro-NH₂,

(N-carboxyethyl)Gly-Pro-NH₂,

(N-1,3-dicarboxypropyl)Gly-Pro-NH₂,

(N-methyl)Leu-Pro-NH₂, Leu-NH₂, and Leu-OH.

Inventors: Al-Obeidi et al. Serial No.: 09/211,715 Filed: December 14, 1998 Page 8

11. (amendea) A compound selected from the group consisting of

Alloc-pAph-Chg-Pal(3)Me-NHs; (2-quinolinoy1)-pAph-Chg-Pal(3)Me-NH-; Ac-pAph-Chq-Pal(3)Me-NH(1-methoxycarbonyl) -1-cyclohexyl; Ac-pAph-Cha-Arq-NHa; (2-pyridoyl)-pAph-Chg-Pal(3)Me-NHo; $CF_3C(O) = (iBu) Phe(pNH_a) = Chg = Arg = NH_a;$ Ab-pAph-Chq-Pal(B)Me-NH-(1-methoxydarbonyl) -1-cyclopentyl; Ac-pAph-Chq-Pal(3)Me-NH-(4-methoxycarbonyl -cyclohexyl)methyl; Ad-pAph-Chq-Pal(3)Me-NH-(3-thienyl-2 -carboxylic acid methyl ester); Ac-pAph-Chg-Arg-NH; CF₃C(O) - (iBu) Tyr-Chg-Arg-OH; Ac-pAph-Chq-Pal(3)Me-NH-(4-methoxycarbonyl -cyclohexyl) methyl; Ac-pAph-Chg-Pal(3)Me-NHo; Ac-pAph-Chg-Pal(3)(CH-COOH)-NH-; (2-quinolinecarboxy)-pAph-Chq-Pal(3)Me-NH-; Ac-pAph-Chg-Pal(3)Me-NH-(4-carboxycyclohexyl) methyl; and CF₀C(O)(iBu)-Tyr-Ile-Arg-NH₀.

21. (amended) A compound Ac-D-pAph-Chg-Pal(3)Me-Leu-Pro-NH.

1